An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis — Stella

Recruiting

Back to Psychosis Associated With Alzheimer's Disease trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(3 sites)

United States

Clinical Site, Doral, Florida

Clinical Site, Miami, Florida

Clinical Site, Miami, Florida

Key details

Phase

Safety & dosing

Sponsor

MapLight Therapeutics

Enrollment target

~210 participants

Started

March 2026

Primary completion

March 2029

Age range

55 Years – 91 Years

Last updated April 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov